PACIRA BIOSCIENCES, INC. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
PACIRA BIOSCIENCES, INC. (PCRX) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $6.85 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-02-26
- PACIRA BIOSCIENCES, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was $6.85M, a 52.52% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was $14.43M.
- PACIRA BIOSCIENCES, INC. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was -$21.61M.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|
| 2025-12-31 | $6.85M 10-K · filed 2026-02-26 |
| 2024-12-31 | $14.43M 10-K · filed 2026-02-26 |
| 2023-12-31 | -$21.61M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |